Rathbones Group PLC Centessa Pharmaceuticals PLC Transaction History
Rathbones Group PLC
- $19.7 Billion
- Q1 2025
A detailed history of Rathbones Group PLC transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Rathbones Group PLC holds 16,500 shares of CNTA stock, worth $195,690. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,500
Previous 16,650
0.9%
Holding current value
$195,690
Previous $278,000
14.75%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CNTA
# of Institutions
142Shares Held
124MCall Options Held
163KPut Options Held
816K-
Medicxi Ventures Management (Jersey) LTD20MShares$237 Million75.25% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$118 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$115 Million4.7% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.95MShares$82.5 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X05.92MShares$70.2 Million0.05% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.12B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...